GLP-1 Drugs and Vision Loss: What You Need to Know

Jessi Macdonald was scrolling through social media when she saw a post about GLP-1 drugs and an increased risk of vision loss.

“I called my doctor immediately,” she said. Macdonald is one of the nearly 21 million women in the U.S. who take GLP-1. She said the weight loss drug has changed her life and she doesn’t want to stop taking it. But the headline gave her pause.

In early November, the Food and Drug Administration (FDA) announced that it was requiring all manufacturers of GLP-1 to add to the drugs’ warning labels the potential increased risk of nonarteritic anterior ischemic optic neuropathy (NAION), an eye disease that causes vision loss.

So should you be concerned about your eye health when taking GLP-1? Here’s what you need to know about NAION and what you should consider regarding your eye health and GLP-1.

What is NAION?

Nonarteritic anterior ischemic optic neuropathy (NAION) is an eye disease that causes painless, sudden loss of vision in one eye.

NAION occurs when there is a sudden blockage or reduction in blood flow to the front part of the optic nerve, also called the optic disc. “Basically it’s a small stroke in the eye,” said Dr. Karen Allison, associate professor of ophthalmology at the Flaum Eye Institute at the University of Rochester and board member of the organization Prevent Blindness.

NAION occurs without warning – most people notice the change when they wake up in the morning – and the vision loss is usually permanent.

The good news is that NAION is a rare disease. “The risk is low – it doesn’t matter whether you take GLP-1 or not,” Allison said. “The risk is highest in people who have underlying vascular risk factors such as diabetes, high blood pressure, sleep apnea or a crowded optic disc and are older.”

What led to the NAION warning on GLP-1 drugs?

The FDA recently analyzed several studies to examine the connection between NAION and GLP-1 drugs.

A meta-analysis of 126 studies found that people prescribed GLP-1 semaglutide for type 2 diabetes or obesity had a potentially increased risk of NAION compared to people taking other antidiabetic or weight loss medications. The estimated rate was 6.4 cases per 100,000 people taking a GLP-1 drug, compared with 3.8 cases in people taking a placebo or non-GLP-1 diabetes drug.

Another study, a 2025 analysis of 37.1 million people with type 2 diabetes, also found an increased risk when taking GLP-1 semaglutide compared to other blood sugar-lowering medications.

But the key word in research is association. “The association is so concerning that it warrants further investigation, but it is important that we emphasize that an association does not necessarily prove a causal relationship,” Allison said. “Researchers are still trying to determine whether the drug contributes to NAION or whether it is due to underlying conditions. The FDA warning is simply to make people aware of the connection.”

Outside of NAION, some studies have found a link between GLP-1 and eye diseases such as worsening diabetic retinopathy, macular edema, vitreous hemorrhages, and vision problems. However, the possible effects of GLP-1 on eye health are still being researched.

GLP-1 and eye health

We know that GLP-1 drugs are primarily prescribed to people with type 2 diabetes and obesity, and both conditions can affect eye health.

In people with type 2 diabetes, high blood sugar levels can damage the tissue and blood vessels in the eyes and cause vision loss. In fact, diabetes is the leading cause of blindness in people ages 18 to 64.

When it comes to obesity, Allison noted that people living with the disease are at increased risk of diabetes and other conditions such as high blood pressure and sleep apnea – all of which can affect the vascular system and cause eye damage.

So if you have diabetes, obesity, or another condition for which GLP-1 medications are prescribed, it’s important to get an eye exam at least once a year to check for problems.

A comprehensive eye exam can also show whether you have a crowded optic nerve head, also called a “risk disc,” which can increase your risk of NAION. “Because there are no symptoms of NAION, you want to receive proactive treatment or evaluation,” Allison said.

For most people, taking a GLP-1 medication helps treat underlying causes that are harming eye health. But how GLP-1 might impact long-term eye health is still being studied. “We don’t want people to be afraid and not take GLP-1 medications, but it is very important that people know if they are experiencing any changes so that their vision can be checked immediately,” Allison said.